Immunomodulatory drugs enhance cytotoxicity and immunogenic cell death in multiple myeloma, implying that targeting mTORC1 could improve treatment outcomes.
Key Points
This research aims to elucidate the mechanisms by which immunomodulatory drugs induce therapeutic effects in multiple myeloma.
Performed RNA sequencing on multiple myeloma cells treated with immunomodulatory drugs.
Analyzed clinical datasets correlating mTOR/p70S6K expression with patient outcomes.
Investigated the role of AMPK and CHEK1 in mTORC1 signaling and DNA damage response.
IMiDs activated AMPK and suppressed mTORC1 signaling, enhancing autophagy and CRBN expression.
Low CHEK1 expression correlated with prolonged patient survival and increased DNA damage.
Treatment with IMiDs activated the cGAS-STING pathway, promoting immunogenic cell death markers.